Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Mecasermin - Ipsen

Drug Profile

Mecasermin - Ipsen

Alternative Names: FK 780; IGF-1; Increlex; Insulin-like growth factor-1; rhIGF-I; Somatomedin-1

Latest Information Update: 12 Sep 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Genentech
  • Developer Ipsen; Ipsen Biopharmaceuticals; Tercica
  • Class Antihyperglycaemics; Growth factors; Peptides
  • Mechanism of Action Insulin-like growth factor I stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Short stature
  • New Molecular Entity No

Highest Development Phases

  • Marketed Short stature
  • Discontinued Diabetes mellitus

Most Recent Events

  • 16 Feb 2016 Biomarkers information updated
  • 09 May 2014 9162573 - sale figures for North America - haven't added
  • 26 Feb 2013 Tercica is now called Ipsen Biopharmaceuticals
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top